Rifalazil (also known as KRM-1648 and AMI-1648) is an antibiotic. Rifalazil kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil is used as treatments for many different diseases. Of the most common are chlamydia, CDAD, and TB. Using rifalazil and the effects that coincide with taking rifalazil for treating a bacterial disease vary from person to person, as does any drug put into the human body. Food interactions and genetic variation are a few causes for the variation in side effects from the use of rifalazil.〔http://www.healthanddna.com/drug-safety-dna-testing/rifalazil-side-effects〕
== Biological Properties ==
Rifalazil works well alone, and in conjunction with other antibiotics alone. In a study conducted in 2005, it was found that combining rifalazil with vancomycin increased bacterial killing by a factor of 3. Rifalazil also has a very long half-life which allows more infrequent dosages as opposed to frequent small dosages of antibiotics.
Many different studies have been conducted that researched the effect of rifalazil on certain strains of bacterial diseases. In a study conducted in 2004, it was found that rifalazil reduces ''C. difficile'' strains when studied ''in vitro''.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
| 翻訳と辞書 : 翻訳のためのインターネットリソース|
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.